Bio View (Israel) Performance
| BIOV Stock | ILS 31.80 0.80 2.58% |
On a scale of 0 to 100, Bio View holds a performance score of 12. The firm shows a Beta (market volatility) of -0.41, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Bio View are expected to decrease at a much lower rate. During the bear market, Bio View is likely to outperform the market. Please check Bio View's standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Bio View's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bio View are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bio View sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 17.2 M | |
| Total Cashflows From Investing Activities | -740 K |
Bio |
Bio View Relative Risk vs. Return Landscape
If you would invest 2,530 in Bio View on November 27, 2024 and sell it today you would earn a total of 650.00 from holding Bio View or generate 25.69% return on investment over 90 days. Bio View is generating 0.4934% of daily returns and assumes 3.0077% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than Bio, and 91% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bio View Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio View's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio View, and traders can use it to determine the average amount a Bio View's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.164
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIOV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.01 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.49 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Bio View is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio View by adding it to a well-diversified portfolio.
Bio View Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio View, and Bio View fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 35.4 M | |||
| Shares Outstanding | 13.75 M | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 1.71 X | |||
| Revenue | 30.51 M | |||
| EBITDA | 4.72 M | |||
| Cash And Equivalents | 17.67 M | |||
| Cash Per Share | 1.24 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 11.80 % | |||
| Book Value Per Share | 2.00 X | |||
| Cash Flow From Operations | 3.25 M | |||
| Earnings Per Share | 0.09 X | |||
| Total Asset | 40.02 M | |||
| Retained Earnings | (29 M) | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
About Bio View Performance
By analyzing Bio View's fundamental ratios, stakeholders can gain valuable insights into Bio View's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio View has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio View has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel.Things to note about Bio View performance evaluation
Checking the ongoing alerts about Bio View for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio View help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio View had very high historical volatility over the last 90 days | |
| About 52.0% of the company shares are held by company insiders |
- Analyzing Bio View's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio View's stock is overvalued or undervalued compared to its peers.
- Examining Bio View's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio View's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio View's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio View's stock. These opinions can provide insight into Bio View's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio View's price analysis, check to measure Bio View's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio View is operating at the current time. Most of Bio View's value examination focuses on studying past and present price action to predict the probability of Bio View's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio View's price. Additionally, you may evaluate how the addition of Bio View to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |